GC
LSTA icon

Globeflex Capital’s Lisata Therapeutics LSTA Stock Holding History

Globeflex Capital’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3
Closed – – 505
2016
Q4 		$0 Hold
3
– – ﹤0.01% 515
2016
Q3 		$0 Hold
3
– – ﹤0.01% 520
2016
Q2 		$0 Hold
3
– – ﹤0.01% 491
2016
Q1 		$0 Hold
3
– – ﹤0.01% 470
2015
Q4 		$0 Buy
+3
New +$551 ﹤0.01% 479

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Globeflex Capital's LSTA Position: Q1 2017 in Review

Globeflex Capital sold out of Lisata Therapeutics (LSTA) in Q1 2017, closing a stake of 3 shares.

Globeflex Capital first reported a position in LSTA in Q4 2015 and held it in 5 quarters. The position peaked at $0 in Q4 2016. 24 funds tracked by Wall St. Rank hold LSTA as of Q1 2017.

  • Globeflex Capital reported no remaining Lisata Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Globeflex Capital sold 3 Lisata Therapeutics shares in Q1 2017.
  • Globeflex Capital first reported a position in Lisata Therapeutics in Q4 2015 and held it in 5 quarters.
  • Globeflex Capital's Lisata Therapeutics position peaked at $0 in Q4 2016.
  • 24 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2017.

Based on Globeflex Capital's 13F filing for Q1 2017, filed 12 May 2017.